CatalystFixed Income

ARS PHARMA TARGETS CASH FLOW BREAKEVEN BY END OF 2027 AS IT CUTS CASH-BASED SG&A AND R&D TO $100M-$110M IN H2 2026 - SEEKINGALPHA

Cash flow breakeven target by 2027 with SG&A/R&D cuts to $100M-$110M signals major cost discipline.

What changed

Cash flow breakeven target by 2027 with SG&A/R&D cuts to $100M-$110M signals major cost discipline.

Why it matters

Cash flow breakeven target by 2027 with SG&A/R&D cuts to $100M-$110M signals major cost discipline. — impact context not separately stored; see What changed.

Sources

seekingalpha